Tesamorelin

Researchers who buy Tesamorelin research peptide are typically studying its behavior as a synthetic analog of growth hormone-releasing hormone (GHRH), structurally modified from the native GHRH(1-44) sequence for extended stability. Tesamorelin is one of the most extensively studied GHRH-analog research compounds in the published literature, including in controlled human clinical trials. The summary below reflects the published preclinical and clinical literature and is provided strictly for research and educational reference — it does not describe an intended effect of this product in humans or animals.

In this reference:

• What Is Tesamorelin?
• Proposed Mechanism of Action
• Chemical Identity
• Purity, Storage & Quality
• Research Applications
• What the Human Evidence Shows
• Compared to Related Research Compounds
• Frequently Asked Questions

What Is Tesamorelin?

Tesamorelin is a synthetic 44-amino-acid peptide analog of growth hormone-releasing hormone (GHRH), modified from the native GHRH(1-44) sequence with a trans-3-hexenoic acid addition at the N-terminus to resist enzymatic degradation and extend biological activity relative to unmodified GHRH fragments such as Sermorelin.

Researchers should be aware that Tesamorelin has a pharmaceutical-development history distinct from most other compounds in this catalog: an injectable formulation (brand name Egrifta, later reformulated as Egrifta SV) received FDA approval in 2010 for a specific, narrow indication — reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. That approval history is referenced here for research context only. It applies to a specific pharmaceutical-grade formulation manufactured and controlled under an FDA-approved manufacturing and prescribing pathway, and is entirely distinct from the research-use-only material sold on this page.

Proposed Mechanism of Action

Published research describes Tesamorelin as binding to the growth-hormone-releasing hormone receptor (GHRHR) on pituitary somatotroph cells, stimulating pulsatile growth hormone secretion and subsequent hepatic IGF-1 production through the same receptor pathway as native GHRH and Sermorelin. Because the modified N-terminus resists the enzymatic cleavage that rapidly degrades unmodified GHRH(1-29)/(1-44) sequences, published pharmacokinetic literature describes Tesamorelin as producing a more sustained GH/IGF-1 elevation than earlier-generation GHRH fragments in tested models.

The clinical research base has focused specifically on downstream effects on visceral adipose tissue (VAT) and hepatic fat, proposed in the literature to result from GH-axis-mediated shifts in lipid metabolism favoring reduction of centrally-distributed fat depots. A 2026 meta-analysis pooling five randomized controlled trials reported a statistically significant reduction in visceral adipose tissue (mean difference −27.71 cm², 95% CI −38.37 to −17.06; P<0.001) associated with tesamorelin administration, alongside reductions in trunk fat, waist circumference, and hepatic fat, and a modest increase in lean body mass — reported without significant worsening of glycemic or lipid parameters in the pooled analysis (PMID 41545261).

Chemical Identity

Sequence Basis	Modified GHRH(1-44) analog
Molecular Formula	C221H366N72O67S
Molecular Weight	~5135.9 g/mol
Appearance	White to off-white lyophilized powder

Purity, Storage & Quality

First Class Science supplies this Tesamorelin research peptide vial at research-grade purity, verified by independent third-party HPLC testing and mass spectrometry. A Certificate of Analysis is available for every batch at our Certificate of Analysis page, listing the specific lot’s purity result, molecular-weight confirmation, and test date.

Store the lyophilized (freeze-dried) compound at −20°C for long-term stability. This vial must be reconstituted with bacteriostatic or sterile water before laboratory use; after reconstitution, refrigerate at 2–8°C and use within 4–6 weeks. Avoid repeated freeze-thaw cycles and prolonged exposure to light or room-temperature conditions, both of which are associated with accelerated peptide degradation in handling literature.

Important: This item is manufactured strictly for research purposes. It is not intended for human or veterinary use and is distributed solely for laboratory and scientific investigation.

Preparing Solutions for Laboratory Use

Laboratories reconstituting lyophilized Tesamorelin for in vitro or animal-model research typically follow standard peptide-handling practice: the vial is brought to room temperature before opening, and a diluent — commonly reconstitution solution or sterile water for injection (SWFI) — is added slowly down the interior wall of the vial rather than directly onto the lyophilized material, to reduce foaming and mechanical stress on the peptide. The vial is then gently swirled, never shaken, until the powder is fully dissolved.

Stock-solution concentration for a given protocol is calculated by dividing the total peptide mass in the vial by the volume of diluent added, and that calculation should be recorded in the study’s protocol documentation. This page describes general laboratory reconstitution practice for research use and is not a dosing guide for human or animal administration.

Quality Control Methodology

Each production batch of this Tesamorelin research peptide undergoes independent third-party testing before release. High-performance liquid chromatography (HPLC) confirms purity by measuring the proportion of the target peptide relative to synthesis by-products or degradation fragments. Mass spectrometry separately confirms molecular identity, verifying that the measured mass of the material matches the expected ~5135.9 g/mol molecular weight of Tesamorelin. Both results are recorded on the batch’s published Certificate of Analysis, letting researchers independently verify identity and purity rather than relying on manufacturer claims alone.

Who Should Buy Tesamorelin Research Peptide

Researchers who buy Tesamorelin from First Class Science are typically university and academic laboratories, contract research organizations (CROs), and biotechnology R&D teams running animal-model or in vitro studies on GHRH-receptor pharmacology, GH-axis signaling, and adipose-tissue metabolism. First Class Science requires that all research-peptide orders be placed by parties who acknowledge and agree to the research-use-only terms stated on this page prior to purchase.

Research Applications

The published literature on Tesamorelin spans several distinct research areas. Each is summarized below strictly as a description of what has been studied in animal, in vitro, or controlled clinical-trial models — not as a claim about effects for any individual using this product.

GHRH-Receptor Pharmacology and Extended-Stability Analog Research

Tesamorelin’s N-terminal modification is studied as a structure-activity model for extending GHRH-analog half-life relative to unmodified fragments, informing broader research on peptide-stability engineering in the GHRH-analog research-compound class.

Visceral Adipose Tissue and Metabolic Research

The bulk of the published clinical literature has focused on Tesamorelin’s association with reductions in visceral adipose tissue, trunk fat, and hepatic fat in a specific patient population (detailed in the Human Evidence section below), providing extensive downstream metabolic data for researchers studying GH-axis-mediated adipose-tissue regulation.

Comparative GHRH-Analog Research

Because Tesamorelin, Sermorelin, and CJC-1295 all act on the same GHRHR receptor but differ in structural modification and half-life, published and vendor-adjacent comparative literature frequently positions Tesamorelin as a reference point for studying how N-terminal and backbone modifications affect GHRH-analog pharmacokinetics.

What the Human Evidence Shows

Researchers evaluating Tesamorelin should know that it has one of the most substantial controlled human clinical-trial records of any compound in this catalog — because, unlike most research peptides, a pharmaceutical-grade formulation completed the FDA approval pathway for a specific indication. The pivotal randomized, double-blind, placebo-controlled trial enrolled HIV-infected patients with excess abdominal fat and reported that tesamorelin significantly reduced visceral adipose tissue and improved trunk fat proportion relative to placebo over 26 weeks, with the treatment effect maintained through extension to 52 weeks (Falutz J, et al., N Engl J Med. 2007;357(23):2359-2370; PMID 18057338). A more recent 2026 meta-analysis pooling five RCTs confirmed this VAT-reduction finding across the accumulated trial base (PMID 41545261, cited above).

This clinical record relates specifically to a pharmaceutical-grade, FDA-approved formulation (Egrifta/Egrifta SV) manufactured and prescribed under a distinct regulatory pathway for a narrow, specific indication — it does not establish safety or efficacy for the research-grade Tesamorelin sold on this page, and does not support human self-administration outside that approved formulation’s prescribing context. Tesamorelin as supplied here is sold strictly for laboratory research use and is not distributed, labeled, or intended as the approved pharmaceutical product.

This distinction matters for how findings from this page should be characterized. A researcher citing the Falutz trial or the 2026 meta-analysis in a grant application or protocol design should describe them accurately as reflecting a distinct, FDA-approved pharmaceutical formulation’s clinical-trial record in a specific patient population, not as safety or efficacy data for the vendor-supplied research compound sold here.

Compared to Related Research Compounds

Tesamorelin is frequently studied alongside, or in fixed-ratio combination with, other GH-axis research peptides. First Class Science supplies several related preparations for researchers running comparative studies:

Ipamorelin – 10mg is a selective ghrelin-receptor (GHS-R1a) agonist studied through a distinct receptor pathway from Tesamorelin’s GHRH-receptor mechanism; a Tesamorelin / Ipamorelin Blend – 5/5mg and 10/10mg preparation are available for protocols modeling combined dual-receptor GH-axis stimulation.

Sermorelin – 10mg is the unmodified GHRH(1-29) fragment, useful as a comparator for studying how Tesamorelin’s structural modification affects half-life and receptor engagement relative to native GHRH sequences.

A Tesamorelin / CJC-1295 (No DAC) / Ipamorelin Blend is also available for laboratories running triple-compound comparative protocols across all three GH-axis mechanisms represented in this catalog.

Each of these related preparations carries its own Certificate of Analysis and is subject to the same research-use-only terms described on this page.

Common Research Study Designs

Published studies referenced throughout this page typically fall into one of three designs: in vitro GHRHR receptor-binding and pharmacokinetic-stability assays; controlled multicenter randomized human trials in a specific HIV-lipodystrophy patient population (the pharmaceutical-development record); and pooled meta-analyses aggregating that trial base. Understanding which design underlies a given finding is important context for interpreting the strength of any individual claim in the literature.

Frequently Asked Questions

What is the purity of this Tesamorelin research peptide?
Every batch is independently verified via third-party HPLC and mass-spectrometry testing, with a Certificate of Analysis published for each lot.

How should Tesamorelin research peptide be stored?
Store the lyophilized powder at −20°C. After reconstitution, refrigerate at 2–8°C and use within 4–6 weeks; avoid repeated freeze-thaw cycles.

Is Tesamorelin approved for human or animal use?
A distinct pharmaceutical-grade formulation (Egrifta/Egrifta SV) is FDA-approved for a specific indication (reduction of excess abdominal fat in HIV-associated lipodystrophy). That approval does not extend to the research-grade Tesamorelin sold on this page, which is distributed strictly for laboratory research use and is not an approved product itself.

Has Tesamorelin been tested in humans at all?
Yes, extensively, in the pharmaceutical-development context described above: a pivotal randomized controlled trial (PMID 18057338) and a 2026 meta-analysis of five RCTs (PMID 41545261) documented its effects on visceral adipose tissue in HIV-infected patients with lipodystrophy. This research relates to the approved pharmaceutical formulation, not the research compound sold here.

How does Tesamorelin differ from Sermorelin?
Both are GHRH-receptor agonists. Sermorelin is the unmodified GHRH(1-29) fragment with a short half-life. Tesamorelin carries an N-terminal modification designed to resist enzymatic degradation and extend biological activity relative to Sermorelin in tested models.

What does the Certificate of Analysis show?
The Certificate of Analysis published for each batch shows the HPLC purity result, mass-spectrometry molecular-weight confirmation, lot number, and test date, allowing researchers to independently verify the identity and purity of the specific batch they receive.

Can Tesamorelin research peptide be shipped internationally?
Shipping availability and any import restrictions for research peptides vary by destination country and are subject to change; researchers should confirm their local import regulations for research-use-only compounds before ordering.

Shipping, Handling & Compliance

This Tesamorelin research peptide ships as a lyophilized powder in a sealed glass vial, packaged to maintain cold-chain integrity in transit where applicable. All orders are subject to the research-use-only terms stated on this page, and First Class Science does not sell this or any other research peptide for human or veterinary administration under any circumstance.

Order tracking, batch-specific documentation requests, and general product questions can be directed to First Class Science customer support, which can confirm current lead times and any destination-specific documentation a receiving institution may require for its own compliance records.

Disclaimer: The research summarized above is drawn from third-party published studies conducted in animal, in vitro, or controlled clinical-trial contexts. It is provided for research and educational reference only and does not describe an intended use, effect, or benefit of this product for any person or animal.

⊗ ALL ITEMS ARE SOLD FOR RESEARCH USE ONLY. This category covers strictly in vitro laboratory testing and scientific experimentation. Content on this site is for education only and does not authorize human or animal use of any kind, which is prohibited by law. Only trained, licensed professionals should handle these materials. Nothing sold here qualifies as a drug, food, or cosmetic, and none of it may be labeled, advertised, or used as such.